Overview

This trial is active, not recruiting.

Condition retinoblastoma
Sponsor National Cancer Institute (NCI)
Start date November 1993
Trial size 1995 participants
Trial identifier NCT00342797, 999993033, OH93-NC-N033

Summary

A series of 1,729 retinoblastoma (RB) patients were identified from medical records at hospital centers in Boston (1937-84) and New York (1914-84). The study cohort consists of the 1,604 patients who survived at least 1 year after RB diagnosis. Information was obtained from medical records and interviews conducted in 1987 and 1993. RB patients had a 30-fold excess risk of another cancer, and a 50% chance of developing a cancer if they survived to 50 years of age. Blood samples have been collected from 481 patients, and studies are underway to determine if certain mutations in the RB1 genes are associated with increased or decreased penetrance or with increased risk of subsequent cancer development. The study population in New York is being expanded currently to include patients treated since 1984, and their medical records are being abstracted. Blood samples will be collected from the newly identified patients who are returning to New York Hospital for a followup RB exam.

United States No locations recruiting
Other Countries No locations recruiting

Eligibility Criteria

Male or female participants from 8 years up to 80 years old.

- INCLUSION CRITERIA: Children treated for retroblastoma over the past 30-plus years.

Additional Information

Official title Retinoblastoma Biomarker Study
Principal investigator Ruth A Kleinrock
Description A series of 1,729 retinoblastoma (RB) patients were identified from medical records at hospital centers in Boston (1937-84) and New York (1914-84). The study cohort consists of the 1,604 patients who survived at least 1 year after RB diagnosis. Information was obtained from medical records and interviews conducted in 1987 and 1993. RB patients had a 30-fold excess risk of another cancer, and a 50% chance of developing a cancer if they survived to 50 years of age. Blood samples have been collected from 481 patients, and studies are underway to determine if certain mutations in the RB1 genes are associated with increased or decreased penetrance or with increased risk of subsequent cancer development. The study population in New York is being expanded currently to include patients treated since 1984, and their medical records are being abstracted. Blood samples will be collected from the newly identified patients who are returning to New York Hospital for a followup RB exam.
Trial information was received from ClinicalTrials.gov and was last updated in December 2016.
Information provided to ClinicalTrials.gov by National Institutes of Health Clinical Center (CC).